Related Experiment Video

Updated: May 30, 2026

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader
07:13

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Published on: May 24, 2024

P2Y12 receptor antagonists in acute coronary syndrome: clinical implications of pharmacologic and pharmacogenetic

Mukesh Singh1, Sasikanth Adigopula, Niaz Ahmad

  • 1Department of Cardiology, Chicago Medical School, North Chicago, Illinois, USA. drmukeshsingh@yahoo.com

Recent Patents on Cardiovascular Drug Discovery
|August 25, 2011
PubMed

Insights

Effective antiplatelet medications are crucial for cardiovascular health. This review examines P2Y12 receptor antagonists, highlighting pharmacogenetic differences and clinical implications for managing thrombosis and reducing adverse events.

Area of Science:

  • Cardiovascular pharmacology
  • Thrombosis research
  • Pharmacogenetics

Background:

  • Platelet activation and aggregation are central to thrombosis and vascular occlusions.
  • Antiplatelet therapy is vital for acute coronary syndromes, coronary artery disease, and percutaneous coronary interventions.
  • Residual platelet reactivity increases major adverse cardiovascular events risk, necessitating improved antiplatelet strategies.

Purpose of the Study:

  • To review P2Y12 receptor antagonists.
  • To discuss pharmacologic and pharmacogenetic differences.
  • To explore clinical implications and recent patents.

Main Methods:

  • Literature review of P2Y12 receptor antagonists.
  • Analysis of pharmacologic properties.
  • Examination of pharmacogenetic variations and clinical outcomes.
  • Review of recent patent landscape.

Main Results:

  • P2Y12 receptor antagonists exhibit significant pharmacologic and pharmacogenetic variability.
  • These differences impact clinical efficacy and patient outcomes.
  • Understanding these variations is key to optimizing antiplatelet therapy.
  • Recent patents indicate ongoing innovation in this therapeutic area.

Conclusions:

  • Optimizing P2Y12 receptor antagonist therapy requires consideration of individual patient pharmacogenetics.
  • Further research and development are needed for more effective antiplatelet agents.
  • Addressing residual platelet reactivity is critical for reducing cardiovascular disease burden.

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...